BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of Campath-1H, a monoclonal antibody that targets CD52 on leukemic cells, in children with relapsed or refractory ALL. METHODS: From October 2005 to December 2006, 13 eligible patients were enrolled on the COG phase II study of Campath-1H (ADVL0222). Campath-1H was initially administered as an intravenous infusion over 2 hr, five times per week for 1 week, then three times per week for three additional weeks. Patients with stable disease or better on day 29 could continue on to combination therapy with Campath-1H, methotrexate, and 6-mercaptopurine for two additional cycles. RESULTS: One of 13 patients enrolled had a complete response to Campath-1H and 4 had stable disease. Dose limiting toxicity occurred in two out of nine fully evaluable patients (Grade IV pain and Grade III allergic reaction/hypersensitivity). No patients received combination therapy. Serum Campath-1H concentrations appeared to be somewhat lower in children with ALL compared with adult patients with chronic lymphocytic leukemia. CONCLUSION: Although a single complete response was observed, activity of single agent Campath-1H appears limited. Our study does not support future single agent evaluation of Campath-1H in children with relapsed ALL.
BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of Campath-1H, a monoclonal antibody that targets CD52 on leukemic cells, in children with relapsed or refractory ALL. METHODS: From October 2005 to December 2006, 13 eligible patients were enrolled on the COG phase II study of Campath-1H (ADVL0222). Campath-1H was initially administered as an intravenous infusion over 2 hr, five times per week for 1 week, then three times per week for three additional weeks. Patients with stable disease or better on day 29 could continue on to combination therapy with Campath-1H, methotrexate, and 6-mercaptopurine for two additional cycles. RESULTS: One of 13 patients enrolled had a complete response to Campath-1H and 4 had stable disease. Dose limiting toxicity occurred in two out of nine fully evaluable patients (Grade IV pain and Grade III allergic reaction/hypersensitivity). No patients received combination therapy. Serum Campath-1H concentrations appeared to be somewhat lower in children with ALL compared with adult patients with chronic lymphocytic leukemia. CONCLUSION: Although a single complete response was observed, activity of single agent Campath-1H appears limited. Our study does not support future single agent evaluation of Campath-1H in children with relapsed ALL.
Authors: Thomas Elter; Peter Borchmann; Holger Schulz; Marcel Reiser; Sven Trelle; Roland Schnell; Markus Jensen; Peter Staib; Timo Schinköthe; Hartmut Stützer; Jürgen Rech; Martin Gramatzki; Walter Aulitzky; Ibrahim Hasan; Andreas Josting; Michael Hallek; Andreas Engert Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: Ben Kennedy; Andy Rawstron; Chris Carter; Mary Ryan; Kevin Speed; Guy Lucas; Peter Hillmen Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: K R Rai; C E Freter; R J Mercier; M R Cooper; B S Mitchell; E A Stadtmauer; P Santábarbara; B Wacker; L Brettman Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Geoff Hale; Peppy Rebello; Lee R Brettman; Chris Fegan; Ben Kennedy; Eva Kimby; Mike Leach; Jeanette Lundin; Håkan Mellstedt; Paul Moreton; Andy C Rawstron; Herman Waldmann; Anders Osterborg; Peter Hillmen Journal: Blood Date: 2004-04-15 Impact factor: 22.113
Authors: Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti Journal: Cancer Res Date: 2010-12-21 Impact factor: 12.701
Authors: Viswanath Reddy Belum; Courtney Washington; Christine A Pratilas; Vincent Sibaud; Franck Boralevi; Mario E Lacouture Journal: Pediatr Blood Cancer Date: 2015-02-12 Impact factor: 3.167
Authors: Irene Y Cheung; Brian H Kushner; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Oncoimmunology Date: 2017-07-31 Impact factor: 8.110